Drugs / Blinatumomab
Regulatory milestones approvals, filings & regulatory actions · 14 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed acute lymphoblastic leukemia 1 milestone | |||||
| Filed | US (FDA) | BLINCYTO | acute lymphoblastic leukemia | 2016-03-01 | “today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration ( FDA ) for BLINCYTO ® (blinatumomab)” amgen.com ↗ |
| Filed B-cell acute lymphoblastic leukemia 1 milestone | |||||
| Filed | China (NMPA) | BLINCYTO | B-cell acute lymphoblastic leukemia | 2021-05-06 | “Regulatory activities for KYPROLIS and BLINCYTO are in progress, with new drug applications (NDAs) to the NMPA submitted in the fourth quarter 2019.” beonemedicines.com ↗ “Received acceptance of a sBLA and priority review in China of BLINCYTO® (blinatumomab)” beonemedicines.com ↗ |
| Filed B-lymphoblastic leukemia with MYC rearrangement 1 milestone | |||||
| Filed | US (FDA) | BLINCYTO | B-lymphoblastic leukemia with MYC rearrangement | 2018-02-14 | “The sBLA for BLINCYTO was accepted by the FDA for priority review” amgen.com ↗ |
| Filed refractory precursor T-lymphoblastic lymphoma/leukemia 2 milestones | |||||
| Filed | Japan (PMDA) | — | refractory precursor T-lymphoblastic lymphoma/leukemia | 2018-01-09 | “an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTE® ) antibody construct blinatumomab” astellas.com ↗ |
| Filed | China (NMPA) | BLINCYTO | refractory precursor T-lymphoblastic lymphoma/leukemia | — | “New Drug Applications for KYPROLIS and BLINCYTO have been filed in China.” amgen.com ↗ |
| Approved Indication not stated 4 milestones | |||||
| Label expansions (6) | US (FDA) | BLINCYTO | — | 2016-08-30 – 2024-06-14 | fda.gov ↗ |
| Filed | US (FDA) | BLINCYTO | B-cell precursor ALL with minimal residual disease | 2017-12-07 | “The U.S. Food and Drug Administration ( FDA ) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO” amgen.com ↗ |
| Approved | EU (EMA) | Blincyto | — | 2015-11-23 | europa.eu ↗ |
| Approved | US (FDA) | BLINCYTO | — | 2014-12-03 | fda.gov ↗ |
Trials 151 · started per year
today
US approved 2014
EU approved 2015
1
1
2
2
2
2
4
4
5
15
11
7
8
11
6
10
17
19
22
1
2004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
News releases announcing trial results or a regulatory action · 41
| Date | Issuer | Release |
|---|---|---|
| 2026-05-31 | Ascentage Pharma Group Inc. | Results Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 ascentage.com ↗
The combination regimen demonstrated encouraging clinical activity in patients with relapsed/refractory Ph+ BCP-ALL or CML-LBP, with strong response rates and minimal residual disease (MRD) clearance. |
| 2025-06-15 | Ascentage Pharma Group Inc. | Results EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL ascentage.com ↗
Furthermore, studies on various combinations of olverembatinib (with venetoclax plus azacitidine, the VP regimen, blinatumomab, or inotuzumab ozogamicin) have shown encouraging results that revealed olverembatinib’s potential in offering more treatment options and improved long-term prognoses to patients with Ph+ ALL. |
| 2024-12-07 | Amgen | Results BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) amgen.com ↗
Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. |
| 2024-06-14 | Amgen | Regulatory FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE amgen.com ↗
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO ® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status. |
| 2023-12-08 | Amgen | Results AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023 amgen.com ↗
Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO ® (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm |
| 2023-06-21 | Amgen | Regulatory FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA amgen.com ↗
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO ® (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%, based on additional data from two Phase 3 studies that were submitted. |
| 2022-12-13 | Amgen | Results BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) amgen.com ↗
Treatment with BLINCYTO in addition to consolidation chemotherapy reduced the risk of death by 58% compared to chemotherapy alone. |
| 2022-05-04 | BeOne Medicines | Regulatory BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) beonemedicines.com ↗
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has granted conditional approval of BLINCYTO® (blinatumomab) for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). |
| 2021-12-06 | Amgen | Results Amgen Announces New Data Being Presented At ASH 2021 amgen.com ↗
Updated data from the Phase 3 '215 trial in children with high-risk first relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) showed BLINCYTO improved event-free survival (EFS) and overall survival (OS) versus chemotherapy before allogeneic hematopoietic stem cell transplant (alloHSCT). |
| 2021-03-02 | Amgen | Results BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia amgen.com ↗
BLINCYTO demonstrated significantly prolonged event-free survival (events were defined by relapse, death, second malignancy, or failure to achieve complete remission) compared with chemotherapy. |
| 2020-12-07 | BeOne Medicines | Regulatory BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) beonemedicines.com ↗
With this approval, BLINCYTO has become the first bispecific immunotherapy approved in China. |
| 2019-09-24 | Amgen | Results Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia amgen.com ↗
Enrollment was terminated early due to encouraging efficacy in the BLINCYTO arm and was based on a recommendation from the Independent Data Monitoring Committee (DMC). |
| 2019-06-16 | Amgen | Results Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019 amgen.com ↗
The study found that with a median follow-up of 59.8 months, the median OS for BLINCYTO-treated patients was 36.5 months (95 percent CI: 22 months - not estimable [NE]). |
| 2019-01-22 | Amgen | Regulatory European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO ® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent. |
| 2018-11-16 | Amgen | Regulatory Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗ |
| 2018-09-25 | Amgen | Regulatory BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia amgen.com ↗
Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO ® (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). |
| 2018-09-25 | Astellas Pharma Inc | Regulatory BLINCYTO® FOR DRIP INFUSION 35μg APPROVED IN JAPAN FOR THE TREATMENT OF RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA astellas.com ↗
“Today’s approval of BLINCYTO marks a significant milestone that reinforces our commitment to addressing unmet medical needs of patients and physicians in Japan,” said Steve Sugino, president and representative director of Amgen Astellas. |
| 2018-08-29 | Amgen | Regulatory European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO ® (blinatumomab) |
| 2018-06-19 | Amgen | Regulatory Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label amgen.com ↗ |
| 2018-04-02 | Adaptive Biotechnologies | Regulatory FDA Approves First Therapy for Patients With MRD-Positive ALL adaptivebiotech.com ↗
This new indication marks the first time the FDA has approved a therapy based on MRD status. |
| 2018-03-29 | Amgen | Regulatory FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children amgen.com ↗
BLINCYTO, the first-and-only approved bispecific CD19-directed CD3 T cell engager (BiTE ® ) immunotherapy, is now also the first-and-only therapy to be FDA -approved for MRD. |
| 2018-02-14 | Amgen | Regulatory Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab) amgen.com ↗
The Committee will review results from clinical studies in support of this potential new indication |
| 2018-01-09 | Astellas Pharma Inc | Regulatory Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE® ) Antibody Construct Blinatumomab for Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Japan astellas.com ↗
today announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTE® ) antibody construct blinatumomab |
| 2017-12-07 | Amgen | Results New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers amgen.com ↗
New results to be presented at ASH demonstrate how two Amgen medicines – KYPROLIS and BLINCYTO ® (blinatumomab) – improved OS in adult patients with relapsed multiple myeloma and Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), respectively. |
| 2017-07-11 | Amgen | Regulatory FDA Grants Full Approval for BLINCYTO® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children amgen.com ↗
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration ( FDA ) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO ® (blinatumomab) to include overall survival (OS) data from the Phase 3 TOWER study. |
| 2017-03-29 | Amgen | Results Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
Additionally, results showed that median relapse-free survival (RFS) was 6.7 months (95 percent CI, 4.4 to not estimable [NE] months), with a median follow up of 9.0 months. |
| 2017-03-29 | Amgen | Regulatory FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application amgen.com ↗
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO ® (blinatumomab) to include overall survival (OS) data from the Phase 3 TOWER study. |
| 2017-03-01 | Amgen | Results BLINCYTO® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy amgen.com ↗
Results from the analysis showed that median overall survival (OS) was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO versus four months (95 percent CI: 2.9, 5.3) for SOC (hazard ratio [HR] for death=0.71; p =0.012). |
| 2017-02-14 | Amgen | Regulatory Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗ |
| 2016-09-01 | Amgen | Regulatory FDA Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. |
| 2016-06-10 | Amgen | Results BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
Results from the analysis showed that median OS was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO versus 4 months (95 percent CI: 2.9, 5.3) for SOC (stratified log-rank test p =.012; hazard ratio=0.71). |
| 2016-05-03 | Amgen | Regulatory FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) amgen.com ↗
The FDA's acceptance of the sBLA submission for BLINCYTO reinforces immunotherapy as a potential option for children in need of new treatments to fight this complex disease and help prevent further relapse. |
| 2016-03-01 | Amgen | Regulatory Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) amgen.com ↗ |
| 2016-02-04 | Amgen | Results Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study. |
| 2015-12-07 | Amgen | Results Amgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 2015 amgen.com ↗
Amgen (NASDAQ:AMGN) today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO ® (blinatumomab) in adults with acute lymphoblastic leukemia (ALL). |
| 2015-11-24 | Amgen | Regulatory European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia amgen.com ↗
Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted conditional marketing authorization for BLINCYTO ® (blinatumomab) for the treatment of adults with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). |
| 2015-09-25 | Amgen | Regulatory Amgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe amgen.com ↗ |
| 2015-07-16 | Amgen | Results Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
The investigational study showed blinatumomab monotherapy induced a complete remission or complete remission with partial hematological recovery within two cycles of treatment in a clinically meaningful number of patients. |
| 2014-12-09 | Amgen | Results Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia amgen.com ↗
In one analysis from the '211 study, 40 percent of patients treated with BLINCYTO who achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh) were enabled to proceed to allogeneic hematopoietic stem cell transplant (HSCT). |
| 2014-12-06 | Amgen | Results Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease amgen.com ↗
In the study, 78 percent of patients who received BLINCYTO experienced a complete MRD response (95 percent CI: 69-85 percent), a measure of eradication of residual disease at the molecular level, after one treatment cycle. |
| 2014-12-03 | Amgen | Regulatory FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration ( FDA ) has granted approval of BLINCYTO ™ (blinatumomab) for the treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). |
All press releases naming this drug 42 releases
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 167 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Blinatumomab | “For high-risk patients, a combination of immunotherapy (blinatumomab - a bispecific CD3 / CD19 T-cell activator) and HSCT in the first remission was chosen.” NCT05029531 ↗164“Multiple studies have reported that blinatumomab achieves complete remission rates of 33-50% in refractory/relapsed Ph-negative B-ALL.” NCT07105579 ↗ “Blinatumomab is a CD19×CD3 bispecific T-cell engager (BiTE) administered via intravenous infusion.” NCT07689149 ↗ “Blinatumomab will be given intravenously up to five cycles.” NCT05931757 ↗ “Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone” NCT06773936 ↗ |
| Known as | AMG 103 | “Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®).” NCT04827745 ↗ |
| Known as | Blina | “The induction therapy is a combination of Blinatumomab(Blina), Vindesine(VDS), Cyclophosphamide(CTX) and Dexamethasone(DXM).” NCT06742515 ↗1“including the anti-CD19 bispecific T-cell engager blinatumomab (BLINA, Blincyto®, Amgen).” NCT06860269 ↗ |
| Known as | Blina-14 | “All LR-B-ALL patients will be treated with 14 days of blinatumomab (Blina-14) as early intensification to replace CAT+” NCT06882057 ↗ |
| Known as | BLINCYTO | “Blinatumomab (BLINCYTO) is a bi-specific T-cell engaging (BiTE®) antibody construct that transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell...” NCT03931642 ↗4“Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®).” NCT04827745 ↗ “including the anti-CD19 bispecific T-cell engager blinatumomab (BLINA, Blincyto®, Amgen).” NCT06860269 ↗ “Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager” NCT03173430 ↗ “Blinatumomab Injection [Blincyto]” NCT06250959 ↗ |
| Known as | bscCD19xCD3 | “Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®).” NCT04827745 ↗ |
| Known as | MEDI 538 | “Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)” NCT00676871 ↗ |
| Known as | MT103 | “Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®).” NCT04827745 ↗ |
| Known as | NSC# 765986 | “A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old...” NCT04546399 ↗1“A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy” NCT03914625 ↗ |
| Action | Deplete | “resulting in T-cell activation and a cytotoxic T-cell response against CD19+ cells.” NCT00274742 ↗ |
| Modality | Other / unclassified | “Bispecific T-Cell Engager MEDI-538” NCT00538096 ↗ |
| Route | Intravenous | “by continuous intravenous infusion” NCT00274742 ↗ |
| Target | CD19 | “against CD19 expressing cells” NCT01209286 ↗ |